Abstract
The development of estrogen-induced pituitary prolactinoma in Fischer 344 (F344) rats is associated with enhanced neovascularization. Based on the significance of matrix metalloproteinases (MMPs) for tumor growth and angiogenesis, we have studied the effect of batimastat (BB-94), a synthetic MMPs inhibitor (MMPI) on the progression of prolactin-secreting pituitary adenoma in rats. Pituitary tumors were induced in male F344 rats by s.c. implantation of Silastic tubes containing diethylstilbestrol (DES). The effects of chronic treatment with BB-94 (30 mg/kg b.w.) on pituitary weight, cell proliferation, apoptosis and vascular density were evaluated. We have stated that chronic treatment with batimastat caused a significant reduction in the pituitary weight. Batimastat has been found to decrease cell proliferation evaluated by a number of PCNA-positive stained cell nuclei. A marked increase in the apoptotic index within the pituitary was observed in the study group. Moreover, the density of microvessels identified by CD31 was reduced in the group treated with BB-94. The results of our study provide evidence for an inhibitory effect of batimastat, a synthetic MMPI, on the growth and angiogenesis in an experimental model of human prolactinoma. The ability of BB-94 to suppress established pituitary tumor growth suggests a possible application of MMPIs in the treatment of pituitary adenomas.
Similar content being viewed by others
References
Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798–827
Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, Beliveau R (1999) Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45:1432–1441
Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220–240
Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326:515–517
Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition—a review of anti-tumor activity. Ann Oncol 6:967–974
Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciano A, Brown PD, Giavazzi R (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460–464
Davies B, Brown P, East N, Crimmin MJ, Balkwill FR (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087–2091. Erratum: Cancer Res 53:3652
DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671–677
Elias KA, Weiner RI (1984) Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 81:4549–4553
Farnoud MR, Farhadian F, Samuel JL, Derome P, Peillon F, Li JY (1995) Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int J Cancer 61:27–34
Farnoud MR, Veirana N, Derome P, Peillon F, Li JY (1996) Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Int J Cancer 67:45–53
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59:5356–5364
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501
Heath EI, Grochow LB (2000) Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59:1043–1055
Jugenburg M, Kovacs K, Jugenburg I, Scheithauer BW (1998) Angiogenesis in endocrine neoplasms. Endocr Pathol 8:259–272
Katznelson L, Alexander JM, Klibanski A (1993) Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 76:1089–1094
Knox JD, Bretton L, Lynch T, Bowden GT, Nagle RB (1998) Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 35:248–254
Lei H, Kalluri R, Furth EE, Baker AH, Strauss JF 3rd (1999) Rat amnion type IV collagen composition and metabolism: implications for membrane breakdown. Biol Reprod 60:176–182
Lein M, Jung K, Le DK, Hasan T, Ortel B, Borchert D, Winkelmann B, Schnorr D, Loenings SA (2000) Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 43:77–82
Levy A (1999) Mitosis and apoptosis in anterior pituitary gland: tumour formation or hyperplasia? Baillieres Best Pract Res Clin Endocrinol Metab 13:353–365
Meleń-Mucha G, Winczyk K, Pawlikowski M (1998) Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer. Anticancer Res 18:3615–3620
Minderman T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 41:359–364
Murphy G, Docherty AJP (1992) The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120–125
Páez Pereda M, Ledda MF, Goldberg V, Chervin A, Carrizo G, Molina H, Müller A, Renner U, Podhajcer O, Arzt E, Stalla GK (2000) High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab 85:263–269
Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509
Pereda MP, Goldberg V, Chervin A, Carizzo G, Molina A, Andrada J, Sauer J, Renner U, Stalla GK, Arzt E (1996) Interleukin-2 (IL-2) and IL-6 regulate c-fos protooncogene expression in human pituitary adenoma explants. Mol Cell Endocrinol 124:33–42
Phelps C, Hymer WC (1983) Characterization of oestrogen-induced adenohypophyseal tumors in the Fischer 344 rat. Neuroendocrinology 37:23–31
Sang QX (1998) Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8:171–177
Schechter J, Ahmad N, Elias K, Weiner R (1987) Estrogen-induced tumors: changes in the vasculature in two strains of rat. Am J Anat 179:315–323
Scheithauer BW, Kovacs KT, Laws ER, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733–744
Sledge GW Jr, Qulali M, Goulet R, Bone EA, Fife R (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546–1550
Spady TJ, McComb RD, Shull JD (1999) Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland. Endocrine 11:217–233
Stefaneanu L, Kovacs K, Scheithauer BW, Kontogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R (2000) Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 11:341–352
Stepień H, Grochal M, Zieliński KW, Mucha S, Kunert-Radek J, Kulig A, Stawowy A, Pisarek H (1996) Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99–106
Talbot DC, Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32:2528–2533
Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293–298
Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JAH (2000) Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85:2931–2935
Turner HE (2001) Pituitary tumor angiogenesis. Endocrinologist 11:465–469
Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726–4728
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1–8
Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180
Wiklund J, Wertz N, Gorski J (1981) A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats. Endocrinology 109:1700–1707
Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154
Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193–202
Wyllie AH (1993) Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205–208
Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS (1997) Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367–371
Acknowledgement
This study was supported by a grant from the State Committee for Scientific Research of Poland (KBN) to H. S. (No 4 P05A 04215). All experiments were performed according to our institutional and National Institutes of Health (NIH) guidelines for care and use of research animals.
Author information
Authors and Affiliations
Corresponding author
Additional information
Andrzej Godlewski died during the preparation of the manuscript.
Rights and permissions
About this article
Cite this article
Mucha, S.A., Meleń-Mucha, G., Godlewski, A. et al. Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch 450, 335–341 (2007). https://doi.org/10.1007/s00428-006-0351-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-006-0351-x